Predictors of Cardiovascular Hospitalization in Giant Cell Arteritis: Effect of Statin Exposure. A French Population-based Study

REFERENCES

1. 1.↵
   1. Gran JT,
   2. Myklebust G

   . The incidence of polymyalgia rheumatica and temporal arteritis in the county of Aust Agder, south Norway: a prospective study 1987–94. J Rheumatol 1997;24:1739–43.

   OpenUrlPubMed
2. 2.↵
   1. Evans JM,
   2. Bowles CA,
   3. Bjornsson J,
   4. Mullany CJ,
   5. Hunder GG

   . Thoracic aortic aneurysm and rupture in giant cell arteritis. A descriptive study of 41 cases. Arthritis Rheum 1994;37:1539–47.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Evans JM,
   2. O’Fallon WM,
   3. Hunder GG

   . Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. A population-based study. Ann Intern Med 1995;122:502–7.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Salvarani C,
   2. Cantini F,
   3. Boiardi L,
   4. Hunder GG

   . Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 2002;347:261–71.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Gonzalez-Gay MA,
   2. Garcia-Porrua C,
   3. Piñeiro A,
   4. Pego-Reigosa R,
   5. Llorca J,
   6. Hunder GG

   . Aortic aneurysm and dissection in patients with biopsy-proven giant cell arteritis from northwestern Spain: a population-based study. Medicine 2004;83:335–41.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Mahr AD,
   2. Jover JA,
   3. Spiera RF,
   4. Hernández-García C,
   5. Fernández-Gutiérrez B,
   6. Lavalley MP,
   7. et al.

   Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum 2007;56:2789–97.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Villiger PM,
   2. Adler S,
   3. Kuchen S,
   4. Wermelinger F,
   5. Dan D,
   6. Fiege V,
   7. et al.

   Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2016;387:1921–7.

   OpenUrl
8. 8.↵
   1. Maxwell SR,
   2. Moots RJ,
   3. Kendall MJ

   . Corticosteroids: do they damage the cardiovascular system? Postgrad Med J 1994;70:863–70.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   1. Schäcke H,
   2. Döcke WD,
   3. Asadullah K

   . Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002;96:23–43.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Girod JP,
    2. Brotman DJ

    . Does altered glucocorticoid homeostasis increase cardiovascular risk? Cardiovasc Res 2004;64:217–26.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    1. Souverein PC,
    2. Berard A,
    3. Van Staa TP,
    4. Cooper C,
    5. Egberts AC,
    6. Leufkens HG,
    7. et al.

    Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart 2004;90:859–65.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    1. Wei L,
    2. MacDonald TM,
    3. Walker BR

    . Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 2004;141:764–70.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Christiansen CF,
    2. Christensen S,
    3. Mehnert F,
    4. Cummings SR,
    5. Chapurlat RD,
    6. Sørensen HT

    . Glucocorticoid use and risk of atrial fibrillation or flutter: a population-based, case-control study. Arch Intern Med 2009;169:1677–83.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Rienstra M,
    2. Van Gelder IC

    . Are glucocorticoids a treatment or a risk factor? Nat Rev Cardiol 2010;7:122–3.

    OpenUrlCrossRefPubMed
15. 15.↵
    1. Fardet L,
    2. Petersen I,
    3. Nazareth I

    . Risk of cardiovascular events in people prescribed glucocorticoids with iatrogenic Cushing’s syndrome: cohort study. BMJ 2012;345:e4928.

    OpenUrlAbstract/FREE Full Text
16. 16.↵
    1. Gonzalez-Gay MA,
    2. Rubiera G,
    3. Piñeiro A,
    4. Garcia-Porrua C,
    5. Pego-Reigosa R,
    6. Gonzalez-Juanatey C,
    7. et al.

    Ischemic heart disease in patients from Northwest Spain with biopsy proven giant cell arteritis. A population based study. J Rheumatol 2005;32:502–6.

    OpenUrlAbstract/FREE Full Text
17. 17.↵
    1. Gonzalez-Gay MA,
    2. Vazquez-Rodriguez TR,
    3. Gomez-Acebo I,
    4. Pego-Reigosa R,
    5. Lopez-Diaz MJ,
    6. Vazquez-Triñanes MC,
    7. et al.

    Strokes at time of disease diagnosis in a series of 287 patients with biopsy-proven giant cell arteritis. Medicine 2009;88:227–35.

    OpenUrlCrossRefPubMed
18. 18.↵
    1. Le Page L,
    2. Duhaut P,
    3. Seydoux D,
    4. Bosshard S,
    5. Ecochard R,
    6. Abbas F,
    7. et al.

    [Incidence of cardiovascular events in giant cell arteritis: preliminary results of a prospective double cohort study (GRACG)]. [Article in French] Rev Med Interne 2006;27:98–105.

    OpenUrlCrossRefPubMed
19. 19.↵
    1. Tomasson G,
    2. Peloquin C,
    3. Mohammad A,
    4. Love TJ,
    5. Zhang Y,
    6. Choi HK,
    7. et al.

    Risk for cardiovascular disease early and late after a diagnosis of giant-cell arteritis: a cohort study. Ann Intern Med 2014;160:73–80.

    OpenUrlPubMed
20. 20.↵
    1. Crow RW,
    2. Katz BJ,
    3. Warner JE,
    4. Alder SC,
    5. Zhang K,
    6. Schulman S,
    7. et al.

    Giant cell arteritis and mortality. J Gerontol A Biol Sci Med Sci 2009;64:365–9.

    OpenUrlPubMed
21. 21.↵
    1. Nesher G,
    2. Sonnenblick M,
    3. Friedlander Y

    . Analysis of steroid related complications and mortality in temporal arteritis: a 15-year survey of 43 patients. J Rheumatol 1994;21:1283–6.

    OpenUrlPubMed
22. 22.↵
    1. Uddhammar A,
    2. Eriksson A-L,
    3. Nyström L,
    4. Stenling R,
    5. Rantapää-Dahlqvist S

    . Increased mortality due to cardiovascular disease in patients with giant cell arteritis in northern Sweden. J Rheumatol 2002;29:737–42.

    OpenUrlAbstract/FREE Full Text
23. 23.↵
    1. Ray JG,
    2. Mamdani MM,
    3. Geerts WH

    . Giant cell arteritis and cardiovascular disease in older adults. Heart 2005;91:324–8.

    OpenUrlAbstract/FREE Full Text
24. 24.↵
    1. Nordborg E,
    2. Bengtsson BA

    . Death rates and causes of death in 284 consecutive patients with giant cell arteritis confirmed by biopsy. BMJ 1989;299:549–50.

    OpenUrlFREE Full Text
25. 25.↵
    1. González-Gay MA,
    2. Blanco R,
    3. Abraira V,
    4. García-Porrúa C,
    5. Ibáñez D,
    6. García-Pais MJ,
    7. et al.

    Giant cell arteritis in Lugo, Spain, is associated with low longterm mortality. J Rheumatol 1997;24:2171–6.

    OpenUrlPubMed
26. 26.↵
    1. Nuenninghoff DM,
    2. Hunder GG,
    3. Christianson TJ,
    4. McClelland RL,
    5. Matteson EL

    . Mortality of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. Arthritis Rheum 2003;48:3532–7.

    OpenUrlCrossRefPubMed
27. 27.↵
    1. Moulis G,
    2. Lapeyre-Mestre M,
    3. Palmaro A,
    4. Pugnet G,
    5. Montastruc J-L,
    6. Sailler L

    . French health insurance databases: What interest for medical research? Rev Med Interne 2015;36:411–7.

    OpenUrlCrossRefPubMed
28. 28.↵
    1. Charroin C,
    2. Abelin-Genevois K,
    3. Cunin V,
    4. Berthiller J,
    5. Constant H,
    6. Kohler R,
    7. et al.

    Direct costs associated with the management of progressive early onset scoliosis: estimations based on gold standard technique or with magnetically controlled growing rods. Orthop Traumatol Surg Res 2014;100:469–74.

    OpenUrlCrossRefPubMed
29. 29.↵
    1. Pugnet G,
    2. Sailler L,
    3. Bourrel R,
    4. Montastruc J-L,
    5. Lapeyre-Mestre M

    . Is statin exposure associated with occurrence or better outcome in giant cell arteritis? Results from a French population-based study. J Rheumatol 2015;42:316–22.

    OpenUrlAbstract/FREE Full Text
30. 30.↵
    1. Brefel-Courbon C,
    2. Grolleau S,
    3. Thalamas C,
    4. Bourrel R,
    5. Allaria-Lapierre V,
    6. Loï R,
    7. et al.

    Comparison of chronic analgesic drugs prevalence in Parkinson’s disease, other chronic diseases and the general population. Pain 2009;141:14–8.

    OpenUrlCrossRefPubMed
31. 31.↵
    1. Sweeting MJ,
    2. Sutton AJ,
    3. Lambert PC

    . What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med 2004;23:1351–75.

    OpenUrlCrossRefPubMed
32. 32.↵
    1. Narváez J,
    2. Bernad B,
    3. Nolla JM,
    4. Valverde J

    . Statin therapy does not seem to benefit giant cell arteritis. Semin Arthritis Rheum 2007;36:322–7.

    OpenUrlCrossRefPubMed
33. 33.↵
    1. Schmidt J,
    2. Kermani TA,
    3. Muratore F,
    4. Crowson CS,
    5. Matteson EL,
    6. Warrington KJ

    . Statin use in giant cell arteritis: a retrospective study. J Rheumatol 2013;40:910–5.

    OpenUrlAbstract/FREE Full Text
34. 34.↵
    1. Ungprasert P,
    2. Koster MJ,
    3. Warrington KJ

    . Coronary artery disease in giant cell arteritis: a systematic review and meta-analysis. Semin Arthritis Rheum 2015;44:586–91.

    OpenUrlCrossRefPubMed
35. 35.↵
    1. Udayakumar PD,
    2. Chandran AK,
    3. Crowson CS,
    4. Warrington KJ,
    5. Matteson EL

    . Cardiovascular risk and acute coronary syndrome in giant cell arteritis: a population-based retrospective cohort study. Arthritis Care Res 2015;67:396–402.

    OpenUrlCrossRef
36. 36.↵
    1. Amiri N,
    2. De Vera M,
    3. Choi HK,
    4. Sayre EC,
    5. Avina-Zubieta JA

    . Increased risk of cardiovascular disease in giant cell arteritis: a general population-based study. Rheumatology 2016;55:33–40.

    OpenUrlAbstract/FREE Full Text
37. 37.↵
    1. Graham E,
    2. Holland A,
    3. Avery A,
    4. Russell RW

    . Prognosis in giant-cell arteritis. Br Med J 1981;282:269–71.

    OpenUrlAbstract/FREE Full Text
38. 38.↵
    1. Mukhtyar C,
    2. Guillevin L,
    3. Cid MC,
    4. Dasgupta B,
    5. de Groot K,
    6. Gross W,
    7. et al.

    EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2009;68:318–23.

    OpenUrlAbstract/FREE Full Text
39. 39.↵
    1. Bienvenu B,
    2. Ly KH,
    3. Lambert M,
    4. Agard C,
    5. André M,
    6. Benhamou Y,
    7. et al.

    Management of giant cell arteritis: Recommendations of the French Study Group for Large Vessel Vasculitis (GEFA). Rev Med Interne 2016;37:154–65.

    OpenUrlCrossRefPubMed
40. 40.↵
    1. Martínez-Taboada VM,
    2. López-Hoyos M,
    3. Narvaez J,
    4. Muñoz-Cacho P

    . Effect of antiplatelet/anticoagulant therapy on severe ischemic complications in patients with giant cell arteritis: a cumulative meta-analysis. Autoimmun Rev 2014;13:788–94.

    OpenUrlCrossRefPubMed
41. 41.↵
    1. Narváez J,
    2. Bernad B,
    3. Gómez-Vaquero C,
    4. García-Gómez C,
    5. Roig-Vilaseca D,
    6. Juanola X,
    7. et al.

    Impact of antiplatelet therapy in the development of severe ischemic complications and in the outcome of patients with giant cell arteritis. Clin Exp Rheumatol 2008;26:S57–62.

    OpenUrlPubMed
42. 42.↵
    1. Samson M,
    2. Jacquin A,
    3. Audia S,
    4. Daubail B,
    5. Devilliers H,
    6. Petrella T,
    7. et al.

    Stroke associated with giant cell arteritis: a population-based study. J Neurol Neurosurg Psychiatr 2015;86:216–21.

    OpenUrlAbstract/FREE Full Text
43. 43.↵
    1. Hunder GG,
    2. Bloch DA,
    3. Michel BA,
    4. Stevens MB,
    5. Arend WP,
    6. Calabrese LH,
    7. et al.

    The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990;33:1122–8.

    OpenUrlCrossRefPubMed
44. 44.↵
    1. Nesher G,
    2. Berkun Y,
    3. Mates M,
    4. Baras M,
    5. Rubinow A,
    6. Sonnenblick M

    . Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum 2004;50:1332–7.

    OpenUrlCrossRefPubMed